Skip to main

Jennifer M. Spangle, PhD

${headerImageAssetTitle}

Biography

Jennifer M. Spangle, PhD, is an associate professor in the Department of Radiation Oncology at Emory University School of Medicine. Prior to joining Emory, Dr. Spangle was an instructor of pathology at Dana-Farber Cancer Institute and Harvard Medical School.

Dr. Spangle is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University.

Education

Dr. Spangle earned her PhD in Virology from Harvard Medical School in Boston, Massachusetts. She completed her postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts, where she was the American Cancer Society Lee Denim Postdoctoral Fellow.

Titles & Roles

  • Associate Professor, Department of Radiation Oncology
    Emory University School of Medicine

Research

The Spangle laboratory is committed to understanding how PI3K-mediated regulation of the epigenome contributes to cancer development and modulates treatment response. The PI3K signaling pathways is aberrantly activated in more than 40% of breast and other cancers, and yet mono- and combination therapies resulting in durable PI3K inhibition are still in development. Her research program hopes to utilize PI3K-mediated epigenetic rewiring to identify actionable targets and durable and efficacious combination therapies for the treatment of PI3K-activated cancers. The Spangle lab is specifically focusing on the mechanisms by which H3K4-directed demethylases and methyltransferases mediate resistance to PI3K inhibitors in cancer and how AKT regulates histone phosphorylation and transcriptional competence in normal tissue and how this process is deregulated in cancer.

Grants

Publications

Title/Journal Authors Publication Date

Dynamic In Vivo Mapping of the Methylproteome Using a Chemoenzymatic Approach.

Journal of the American Chemical Society

 J Farhi, B Emenike, RS Lee, K Sad, DV Fawwal, CM Beusch, RB Jones, AK Verma, CY Jones, M Foroozani, M Reeves, KK Parwani, P Bagchi, RB Deal, DJ Katz, AH Corbett, DE Gordon, M Raj, JM Spangle 03/05/2025

Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype.

NAR cancer

 K Sad, DV Fawwal, CY Jones, EJ Hill, KT Skinner, ML Adams, S Lustenberger, RS Lee, SV Lohano, SR Elayavalli, J Farhi, CC Mehta, LD Lemon, MB Fasken, AL Hong, SA Sloan, AH Corbett, JM Spangle 03/01/2025

Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype.

bioRxiv : the preprint server for biology

 K Sad, CY Jones, DV Fawwal, EJ Hill, K Skinner, S Lustenberger, RS Lee, SR Elayavalli, J Farhi, LD Lemon, MB Fasken, AL Hong, SA Sloan, AH Corbett, JM Spangle 08/01/2024

Tertiary Amine Coupling by Oxidation for Selective Labeling of Dimethyl Lysine Post-Translational Modifications.

Journal of the American Chemical Society

 B Emenike, P Czabala, J Farhi, J Swaminathan, EV Anslyn, J Spangle, M Raj 04/17/2024

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.

Communications biology

 K Mittal, GW Cooper, BP Lee, Y Su, KT Skinner, J Shim, HC Jonus, WJ Kim, M Doshi, D Almanza, BD Kynnap, AL Christie, X Yang, GS Cowley, BA Leeper, CL Morton, B Dwivedi, T Lawrence, M Rupji, P Keskula, S Meyer, CM Clinton, M Bhasin, BD Crompton, YY Tseng, JS Boehm, KL Ligon, DE Root, AJ Murphy, DM Weinstock, PC Gokhale, JM Spangle, MN Rivera, EA Mullen, K Stegmaier, KC Goldsmith, WC Hahn, AL Hong 04/08/2024

Tunable fluorescent probes for detecting aldehydes in living systems.

Chemical science

 R Wills, R Shirke, H Hrncir, JM Talbott, K Sad, JM Spangle, AD Gracz, M Raj 03/27/2024

Exploring the Molecular Underpinnings of Cancer-Causing Oncohistone Mutants Using Yeast as a Model.

Journal of fungi (Basel, Switzerland)

 X Zhang, DV Fawwal, JM Spangle, AH Corbett, CY Jones 12/11/2023

Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.

Cancers

 RS Lee, K Sad, DV Fawwal, JM Spangle 08/07/2023

Identification of ligand-receptor pairs that drive human astrocyte development.

Nature neuroscience

 AJ Voss, SN Lanjewar, MM Sampson, A King, EJ Hill, A Sing, C Sojka, TN Bhatia, JM Spangle, SA Sloan 08/01/2023

Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer.

Cancer research communications

 RB Jones, J Farhi, M Adams, KK Parwani, GW Cooper, M Zecevic, RS Lee, AL Hong, JM Spangle 12/01/2022

A Saccharomyces cerevisiae model and screen to define the functional consequences of oncogenic histone missense mutations.

G3 (Bethesda, Md.)

 LD Lemon, S Kannan, KW Mo, M Adams, HG Choi, AOD Gulka, ES Withers, HT Nurelegne, V Gomez, RE Ambrocio, R Tumminkatti, RS Lee, M Wan, MB Fasken, JM Spangle, AH Corbett 07/06/2022

Tunable Amine-Reactive Electrophiles for Selective Profiling of Lysine.

Angewandte Chemie (International ed. in English)

 KC Tang, J Cao, LM Boatner, L Li, J Farhi, KN Houk, J Spangle, KM Backus, M Raj 01/26/2022

Adipocyte-mediated epigenomic instability in human T-ALL cells is cytotoxic and phenocopied by epigenetic-modifying drugs.

Frontiers in cell and developmental biology

 M Lee, DK Geitgey, JAG Hamilton, JM Boss, CD Scharer, JM Spangle, KA Haynes, CJ Henry 01/01/2022

Medulloblastoma and the DNA Damage Response.

Frontiers in oncology

 LF McSwain, KK Parwani, SW Shahab, D Hambardzumyan, TJ MacDonald, JM Spangle, AM Kenney 01/01/2022

Practical advice for mentoring and supporting faculty colleagues in STEM fields: Views from mentor and mentee perspectives.

The Journal of biological chemistry

 JM Spangle, H Ghalei, AH Corbett 09/01/2021

PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.

Proceedings of the National Academy of Sciences of the United States of America

 JM Spangle, T Von, DC Pavlick, A Khotimsky, JJ Zhao, TM Roberts 09/29/2020